Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Hospital Universitario Ramón y Cajal, Madrid, Spain
2024
n=115
publication
Evidence: high
Rodríguez-Jorge Fernando, Fernández-Velasco José Ignacio, Villarrubia Noelia, Gracia-Gil Julia, Fernández Eva, Meca-Lallana Virginia, Díaz-Pérez Carolina, Sainz de la Maza Susana, Pacheco Eva María, Quiroga Ana, Ramió-Torrentà Lluis, Martínez-Yélamos Sergio, Bau Laura, Monreal Enric, López-Real Ana, Rodero-Romero Alexander, Borrega Laura, Díaz Santiago, Eguía Pablo, Espiño Mercedes, Chico-García Juan Luis, Barrero Francisco Javier, Martínez-Ginés María Luisa, García-Domínguez José Manuel, De la Fuente Soraya, Moreno Irene, Sainz-Amo Raquel, Mañé-Martínez M. Alba, Caminero Ana, Castellanos-Pinedo Fernando, Gómez López Ana, Labiano-Fontcuberta Andrés, Ayuso Lucía, Abreu Rossana, Hernández Miguel Ángel, Meca-Lallana José, Martín-Aguilar Lorena, Muriel García Alfonso, Masjuan Jaime, Costa-Frossard Lucienne, Villar Luisa María
Title
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Hypothesis
The study aims to evaluate variations of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and to ascertain the value of both serum biomarkers in predicting response to treatment.
Conclusion
Ocrelizumab induced normalization of sNfL and sGFAP in the majority of NEDA-3 and inflammatory patients but did not cause changes in the PIRA group.